This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health Announces Ten Studies Covering Breast, Colon And Prostate Cancers Accepted For Presentation At The American Society Of Clinical Oncology (ASCO) Annual Meeting

REDWOOD CITY, Calif., May 21, 2013 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from ten studies in breast, colon and prostate cancer, including a large next generation sequencing (NGS) study, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31June 4, 2013 at McCormick Place in Chicago. 


Presentations include:
  • Results from seven studies of the Oncotype DX® breast cancer test expanding the breadth and depth of information about the value of the test and its utility in real-world clinical practice
  • Health economics analysis of the Oncotype DX colon cancer test
  • Initial evaluation using quantitative RT-PCR on gene expression in normal-appearing prostate tissue for prediction of prostate cancer recurrence or death
  • Large NGS study on fixed paraffin-embedded breast cancer tissue to detect fusion transcripts associated with breast cancer progression

The majority of ASCO Annual Meeting abstracts are now publicly available on ASCO's website,

Presentation details are as follows (all times are in Central Daylight Savings Time):

Breast Cancer

Saturday, June 1

Poster Discussion: "The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831" (Abstract #520)
  • Lead Author: Edith A. Perez, M.D., Mayo Clinic Cancer Center
  • Poster Time: 8:00 AM12:00 PM; Discussion Time: 12:00 PM-1:00 PM
  • Location: E Hall D1

Poster Presentation: "Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC)" (Abstract #565)
  • Lead Author: Jeffrey L. Vacirca, M.D., North Shore Hematology/Oncology Associates
  • Session Time: 1:15 PM5:00 PM
  • Location: S Hall A2

Poster Presentation: "ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer" (Abstract #TPS655)
  • Lead Author: Nadia Harbeck, M.D.,  Breast Center University of Munich, Germany
  • Session Time: 1:15 PM5:00 PM
  • Location: S Hall A2

Poster Presentation: "A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer" (Abstract #598)
  • Lead Author: Ciara M. Kelly, M.B., Cork University Hospital
  • Session Time: 1:15 PM5:00 PM
  • Location: S Hall A2

Poster Presentation: "Ethnic differences in tumor proliferation in women with early-stage breast cancer" (Abstract #560)
  • Lead Author: Kevin Kalinsky, M.D., M.S., New York Presbyterian Hospital
  • Session Time: 1:15 PM5:00 PM
  • Location: S Hall A2

Poster Presentation: "Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer" (Abstract #562)
  • Lead Author: Amelia B. Zelnak, M.D., MSc, The Winship Cancer Institute of Emory University
  • Session Time: 1:15 PM5:00 PM
  • Location: S Hall A2

Sunday, June 2, 2013

Oral Presentation: "Prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer" (Abstract #507)
  • Lead Author: Tari A. King, M.D., Memorial Sloan-Kettering Cancer Center
  • Presentation Time: 10:00 AM10:15 AM
  • Location: N Hall B1

Colon Cancer

Sunday, June 2

Poster Presentation: "Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer" (Abstract #3640)
  • Lead Author: Tiffany Yu, B.S., B.A., Cedar Associates LLC
  • Session Time: 8:00 AM11:45 AM
  • Location: S Hall A2

Prostate Cancer

Saturday, June 1

Poster Discussion: "Evidence for a field effect in early prostate cancer (PCa): Gene expression profiles in normal-appearing prostate tissue (NT) adjacent to tumor (T) as predictors of clinical outcome" (Abstract #5029)
  • Lead Author: Eric A. Klein, M.D., Cleveland Clinic
  • Poster Time: 8:00 AM12:00 PM ; Discussion Time: 12:00 PM-1:00 PM
  • Location: Arie Crown Theater

Next Generation Sequencing

Monday, June 3

Poster Discussion: "Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues and its relation to tumor progression" (Abstract: 11018)
  • Lead Author: Yan Ma, Ph.D., Genomic Health, Inc.
  • Poster Time: 8:00 AM12:00 PM ; Discussion Time: 11:30 AM12:30 PM
  • Location: S100A

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.  The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of March 31, 2013, more than 19,000 physicians in over 70 countries had ordered more than 350,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in breast, colon and prostate cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, and follow the company on Twitter @GenomicHealth. To learn more about Oncotype DX tests, visit: and and  

Forward Looking Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to generate similar results in further studies; the applicability of clinical study results to actual outcomes; the ability of any tests the company may develop to optimize cancer treatment; the ability of the company to develop and commercialize additional tests in the future; the scope, success or results of clinical trials and the timing of such activities; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the risks associated with competition; the applicability of clinical study results to actual outcomes; the risks associated with the commercialization of current and future products; the risks and potential delays associated with such studies; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.  

SOURCE Genomic Health, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 0.00%
FB $101.91 0.00%
GOOG $683.11 0.00%
TSLA $150.47 0.00%
YHOO $26.76 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs